search
Back to results

Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration. (MACUPREV)

Primary Purpose

Dry AMD

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Macuprev Group
Placebo Group
Sponsored by
Fondazione G.B. Bietti, IRCCS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry AMD focused on measuring oral supplementation, mfERG, OCT

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age> 50;
  • dry AMD not in therapy with oral supplements or antioxidants
  • visual acuity ≥ 20/40
  • ability to provide written informed consent and to follow the procedures of the study;

Exclusion Criteria:

  • spherical refractive error greater than ±6 diopters
  • cylindrical refractive error greater than ±3 dioptres
  • opacity of diopter means
  • any active or past retinal pathology other than AMD
  • history of ocular surgery (<6 months)
  • Pregnancy

Sites / Locations

  • Fondazione G.B.Bietti

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Macuprev Group

Placebo Group

Arm Description

patients taking oral supplementation (Macuprev) 2 capsules per day for 6 months

patients taking oral placebo 2 capsules per day for 6 months

Outcomes

Primary Outcome Measures

Change of Multifocal electroretinogram (mfERG) in patients with dry age-related macular degeneration after 6 months follow up
To evaluate functional retinal changes of the macular region by multifocal electroretinogram in patients with dry age-related macular degeneration after the use for 6 months of an oral supplementation in tablets based on Ganoderma lucidum (Reishi), Calendula Officinalis, Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid, Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper. The researchers analyzed the average response amplitude densities (RAD: nanoV/ degree 2) between the first negative peak, N1 and the first positive peak, P1

Secondary Outcome Measures

To evaluate correlation between mfERG changes (functional activity) and morphological retinal changes (CRT: central retinal thickness and VD: vessel density at the superficial and deep capillary plexa) after 6 months follow up
The researchers evaluated the linear relationships between the mfERG (Response Amplitude Density (RAD nanoV/degree2) and OCT/OCTA values (CRT in micron and vessel density in mm3) by Pearson's Test after administration of a oral supplementation (Macuprev)

Full Information

First Posted
February 14, 2019
Last Updated
May 7, 2019
Sponsor
Fondazione G.B. Bietti, IRCCS
search

1. Study Identification

Unique Protocol Identification Number
NCT03919019
Brief Title
Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.
Acronym
MACUPREV
Official Title
Evaluation of Macular Function and Related Changes in Visual Perception and Retinal Morphology After 6 Months of Use of Oral Supplementation Called MACUPREV, in Patients With Dry Age-related Macular Degeneration (AMD)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
January 18, 2018 (Actual)
Primary Completion Date
October 19, 2018 (Actual)
Study Completion Date
November 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fondazione G.B. Bietti, IRCCS

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed and therefore an increase in the production of free radicals responsible for tissue damage. The Age-Related Eye Disease Study (AREDS) found that the intake of antioxidants reduces the risk of progression of the disease to an advanced stage (choroidal neovascularization or geographic atrophy ) and reduces the loss of visual acuity. In this study the investigators want to analyze the functional retinal changes (mfERG) of the macular region, in patients with dry age-related macular degeneration, after the use for 6 months of an oral supplementation based on Ganoderma lucidum (Reishi), Calendula Officinalis, Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid, Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry AMD
Keywords
oral supplementation, mfERG, OCT

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
monocentric, prospective, double blind randomized six months study
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Macuprev Group
Arm Type
Experimental
Arm Description
patients taking oral supplementation (Macuprev) 2 capsules per day for 6 months
Arm Title
Placebo Group
Arm Type
Placebo Comparator
Arm Description
patients taking oral placebo 2 capsules per day for 6 months
Intervention Type
Other
Intervention Name(s)
Macuprev Group
Intervention Description
oral supplementation (Macuprev) 2 capsules per day for 6 months
Intervention Type
Other
Intervention Name(s)
Placebo Group
Intervention Description
oral placebo 2 capsules per day for 6 months
Primary Outcome Measure Information:
Title
Change of Multifocal electroretinogram (mfERG) in patients with dry age-related macular degeneration after 6 months follow up
Description
To evaluate functional retinal changes of the macular region by multifocal electroretinogram in patients with dry age-related macular degeneration after the use for 6 months of an oral supplementation in tablets based on Ganoderma lucidum (Reishi), Calendula Officinalis, Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid, Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper. The researchers analyzed the average response amplitude densities (RAD: nanoV/ degree 2) between the first negative peak, N1 and the first positive peak, P1
Time Frame
Functional retinal changes after 6 months follow up
Secondary Outcome Measure Information:
Title
To evaluate correlation between mfERG changes (functional activity) and morphological retinal changes (CRT: central retinal thickness and VD: vessel density at the superficial and deep capillary plexa) after 6 months follow up
Description
The researchers evaluated the linear relationships between the mfERG (Response Amplitude Density (RAD nanoV/degree2) and OCT/OCTA values (CRT in micron and vessel density in mm3) by Pearson's Test after administration of a oral supplementation (Macuprev)
Time Frame
Morpho-functional retinal relationships after 6 months follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age> 50; dry AMD not in therapy with oral supplements or antioxidants visual acuity ≥ 20/40 ability to provide written informed consent and to follow the procedures of the study; Exclusion Criteria: spherical refractive error greater than ±6 diopters cylindrical refractive error greater than ±3 dioptres opacity of diopter means any active or past retinal pathology other than AMD history of ocular surgery (<6 months) Pregnancy
Facility Information:
Facility Name
Fondazione G.B.Bietti
City
Roma
ZIP/Postal Code
00135
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17846363
Citation
Age-Related Eye Disease Study Research Group; SanGiovanni JP, Chew EY, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Sperduto RD. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol. 2007 Sep;125(9):1225-32. doi: 10.1001/archopht.125.9.1225.
Results Reference
background
PubMed Identifier
17716735
Citation
Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S; CARMIS Study Group. Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology. 2008 Feb;115(2):324-333.e2. doi: 10.1016/j.ophtha.2007.05.029. Epub 2007 Aug 22.
Results Reference
background
PubMed Identifier
22009916
Citation
Piermarocchi S, Saviano S, Parisi V, Tedeschi M, Panozzo G, Scarpa G, Boschi G, Lo Giudice G; Carmis Study Group. Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study. Eur J Ophthalmol. 2012 Mar-Apr;22(2):216-25. doi: 10.5301/ejo.5000069.
Results Reference
background
PubMed Identifier
31243641
Citation
Parravano M, Tedeschi M, Manca D, Costanzo E, Di Renzo A, Giorno P, Barbano L, Ziccardi L, Varano M, Parisi V. Effects of Macuprev(R) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up. Adv Ther. 2019 Sep;36(9):2493-2505. doi: 10.1007/s12325-019-01016-2. Epub 2019 Jun 25. Erratum In: Adv Ther. 2019 Nov;36(11):3288.
Results Reference
derived

Learn more about this trial

Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.

We'll reach out to this number within 24 hrs